Trial Profile

A Phase Ib/II Study of APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Other Advanced Solid Tumors

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 17 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Alrizomadlin (Primary) ; Toripalimab (Primary)
Indications Adenoid cystic carcinoma; Liposarcoma; Solid tumours
Focus Adverse reactions; Therapeutic Use
Sponsors Ascentage Pharma

Most Recent Events

02 Jun 2025 According to an Ascentage Pharma media release, abstract from this trial is selected for presentation at ASCO 2025.
23 May 2025 Results published in the Ascentage Pharma Media Release
23 Apr 2025 According to an Ascentage Pharma media release, results of this study have been selected for presentations at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com